20:14 , Oct 5, 2018 |  BC Week In Review  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
12:22 , Oct 1, 2018 |  BC Extra  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
21:49 , Aug 29, 2018 |  BC Extra  |  Preclinical News

Sequential therapies trigger axon regeneration in spinal cord injury

University of California Los Angeles and Swiss Federal Institute of Technology Lausanne (EPFL) researchers showed delivery of three sequential therapies could trigger axon growth after complete spinal cord injury in rodents, suggesting the combination approach...
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
19:43 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity; cachexia Mouse and rat studies suggest GDF15 could help treat obesity, and inhibiting its receptor GFRAL could help treat cachexia. In a mouse model of high-fat diet-induced obesity and a genetic rat model of...
23:12 , Oct 2, 2017 |  BC Extra  |  Preclinical News

NGM targeting GFRAL for both obesity and cachexia

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) plans to develop separate candidates modulating GDNF family receptor alpha like (GFRAL) to treat both obesity and cachexia. In a newly published paper, an NGM team showed GFRAL...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
13:36 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other molecule...